4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease.
Fitzpatrick
Leo R
LR
Penn State College of Medicine, Hummelstown, Pennsylvania 17042, USA. lfitzpatrick@psu.edu
Deml
Ludwig
L
Hofmann
Claudia
C
Small
Jeffrey S
JS
Groeppel
Manfred
M
Hamm
Svetlana
S
Lemstra
Sylvia
S
Leban
Johann
J
Ammendola
Aldo
A
D000208:Acute Disease; D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects; D002908:Chronic Disease; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D016264:Dextran Sulfate / Q000633:toxicity; D003998:Dicarboxylic Acids / Q000494:pharmacology*; D000090722:Dihydroorotate Dehydrogenase; D004195:Disease Models, Animal; D005260:Female; D007124:Immunoenzyme Techniques; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000473:pathology; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D044925:Oxidoreductases Acting on CH-CH Group Donors / Q000037:antagonists & inhibitors; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity
D001713:Biphenyl Compounds; D003998:Dicarboxylic Acids; D000090722:Dihydroorotate Dehydrogenase; D007166:Immunosuppressive Agents; D020381:Interleukin-17; D014302:Trinitrobenzenesulfonic Acid; C553728:vidofludimus; D016264:Dextran Sulfate; D044925:Oxidoreductases Acting on CH-CH Group Donors